cad3-zebov
Vaccineexperimental
Clinical trial activity
9 trials · 21 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Sep 17, 2014 (NCT02240875)
Timeline
Indications
Mechanism of action
- EbolavirusImmunity, active
Ebolavirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cad3-zebov
- ebola chimpanzee adenovirus vector vaccine (cad3-ebo z)
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06803342 | Phase 2 | Jun 26, 2025 | Albert B. Sabin Vaccine Institute, Department of Health and Human Services |
| NCT06036602 | Phase 2 | Feb 29, 2024 | Albert B. Sabin Vaccine Institute, Department of Health and Human Services |
| NCT05909358 | Phase 1/Phase 2 (Phase 2) | Jul 31, 2023 | Epicentre, Government of Uganda, Makerere University, Medical Research Council-UVRI Uganda Research Unit on AIDS |
| NCT04723602 | Phase 1 | Jan 6, 2021 | Albert B. Sabin Vaccine Institute, ICON, Oklahoma Blood Institute |
| NCT04041570 | Phase 1 | Jul 2, 2019 | National Institute of Allergy and Infectious Diseases (NIAID), United States Army |
| NCT02354404 | Phase 1 | Jan 1, 2015 | National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), The EMMES Corporation, United States Army |
| NCT02289027 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2014 | GlaxoSmithKline, Policlinique Médicale Universitaire, University of Basel, University of Lausanne, World Health Organization |
| NCT02267109 | Phase 1 | Oct 1, 2014 | Leidos, National Institute of Allergy and Infectious Diseases (NIAID), University of Maryland, Wellcome Trust |
| NCT02240875 | Phase 1 | Sep 17, 2014 | National Institute of Allergy and Infectious Diseases (NIAID), University of Oxford, Wellcome Trust |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (21)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 4 | 2 | 1 | 2014 |
| Albert B. Sabin Vaccine Institute | Academic/Hospital | 3 | 3 | 2 | 2021 |
| Department of Health and Human Services | Government | 2 | 0 | 1 | 2024 |
| United States Army | Government | 2 | 0 | 1 | 2015 |
| Wellcome Trust | Academic/Hospital | 2 | 0 | 1 | 2014 |
| Epicentre | For profit | 1 | 0 | 1 | 2023 |
| GlaxoSmithKline | For profit | 1 | 0 | 1 | 2014 |
| Government of Uganda | Government | 1 | 0 | 1 | 2023 |
| ICON | For profit | 1 | 0 | 1 | 2021 |
| Leidos | For profit | 1 | 0 | 1 | 2014 |
| Makerere University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Medical Research Council-UVRI Uganda Research Unit on AIDS | Academic/Hospital | 1 | 0 | 1 | 2023 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2015 |
| Oklahoma Blood Institute | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Policlinique Médicale Universitaire | Academic/Hospital | 1 | 0 | 1 | 2014 |
| The EMMES Corporation | For profit | 1 | 0 | 1 | 2015 |
| University of Basel | Academic/Hospital | 1 | 0 | 1 | 2014 |
| University of Lausanne | Academic/Hospital | 1 | 1 | 1 | 2014 |
| University of Maryland | Academic/Hospital | 1 | 1 | 1 | 2014 |
| University of Oxford | Academic/Hospital | 1 | 1 | 1 | 2014 |
21 organizations
Page 1 / 2